**
In a significant revelation, internal records have disclosed that top officials from the Trump administration’s Environmental Protection Agency (EPA) convened with Bayer CEO Bill Anderson last year to discuss the company’s ongoing legal battles over its glyphosate-based herbicides, including Roundup. This meeting occurred just months prior to the administration taking steps that seemed to bolster Bayer’s position in a high-stakes Supreme Court case involving allegations that the company’s products are linked to cancer.
High-Level Meeting Raises Concerns
The meeting, dated 17 June, involved key figures from the EPA, including Lee Zeldin, the agency’s administrator, and Nancy Beck, who previously held a senior role at the American Chemistry Council. The agenda reportedly included discussions about “litigation” and “Supreme Court action,” indicating that Bayer was keen to inform the EPA about its legal strategies as it faces a barrage of lawsuits from individuals claiming that prolonged use of glyphosate has caused their cancer.
Bayer’s legal strategy hinges on a controversial argument: if the EPA does not mandate that glyphosate products carry a cancer warning, the company believes it should not be held liable for failing to provide such a warning. While some courts have sided with Bayer on this issue, others have rejected the argument, leading to a complex legal landscape that continues to evolve.
The implications of this meeting are profound. Critics, including Nathan Donley from the Center for Biological Diversity, have raised alarms over the apparent prioritisation of corporate interests over public health. “It’s becoming abundantly clear that the political appointees at the EPA are more invested in protecting pesticide company profits than the health of Americans,” Donley stated, highlighting the troubling intersection of corporate influence and regulatory oversight.
Administration Actions Following the Meeting
Following the June meeting, the Trump administration’s support for Bayer has taken various forms, raising suspicions about the nature of regulatory practices. In a December filing, the Solicitor General appointed by Trump urged the Supreme Court to hear Bayer’s case, which the court subsequently agreed to. This culminated in a scheduled hearing set for 27 April.
Furthermore, the administration invoked the Defense Production Act, ostensibly to safeguard the production of glyphosate herbicides, effectively granting “immunity” to Bayer and other manufacturers. On 2 March, the government issued an amicus brief in support of Bayer’s position in court, signalling a robust endorsement of the company’s legal arguments.
Bayer maintains that such meetings are standard practice within the regulatory framework. “We have been transparent about our position regarding glyphosate litigation,” a company spokesperson affirmed, while also emphasising that interactions with regulatory bodies are not exclusive to corporate entities.
Public Health Advocates Voice Alarm
The growing evidence of collusion between the Trump administration and Bayer has alarmed public health advocates. Legal experts have voiced concerns regarding the implications of these private meetings. “It’s concerning that the CEO of a major pesticide company can have private meetings with the EPA to talk about limiting the company’s liability,” remarked Whitney Di Bona, a consumer safety advocate. She questioned whether the agency has similarly engaged with the thousands of individuals alleging health harms from glyphosate products.
Renowned historian Naomi Oreskes noted that the meeting exemplifies a troubling trend where industry leaders enjoy privileged access to government officials, while the voices of affected citizens are sidelined. “This pattern of corporate influence on regulation is profoundly troubling,” she stated.
Zen Honeycutt, founder of Moms Across America, expressed her disillusionment with the regulatory process. “Coercion by chemical companies on our regulatory agencies is nothing new,” she asserted, underscoring the disconnect between corporate lobbying efforts and the concerns of grassroots organisations advocating for public health and environmental safety.
Why it Matters
This unfolding saga is emblematic of a broader issue within the realm of environmental regulation and corporate influence. As the Trump administration aligns itself with Bayer, the implications for public health and safety grow increasingly dire. The erosion of rigorous regulatory oversight in favour of corporate interests poses significant risks, not only to those directly affected by glyphosate but to the wider population. This situation serves as a critical reminder of the need for transparency and accountability in the decisions that shape the health of communities across the United States and beyond. The stakes are high, and the fight for justice in the face of corporate power continues.
